Inovio Pharmaceuticals, Inc. (INO)
| Previous close | 20.33 |
| Open | 20.18 |
| Bid | 20.65 x 800 |
| Ask | 20.72 x 1300 |
| Day's range | 19.95 - 20.78 |
| 52-week range | 1.92 - 33.79 |
| Volume | 3,951,357 |
| Avg. volume | 35,615,171 |
| Market cap | 3.275B |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings date | 10 Aug 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.33 |
- Motley Fool
3 Most Popular Coronavirus Stocks on Robinhood: Are They Buys?
Robinhood investors like two fast-growing biotechs and one big pharma company that each have promising COVID-19 vaccine candidates.
- Motley Fool
Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?
Inovio Pharmaceuticals (NASDAQ: INO) is enjoying its best stock performance in seven years thanks to investors' interest in its novel coronavirus vaccine program. VBI Vaccines (NASDAQ: VBIV) appears to be on track for its best year ever -- for the same reason. There are currently 25 COVID-19 vaccine candidates in clinical testing across the world.
- Motley Fool
Better Coronavirus Stock: Pfizer or Inovio Pharmaceuticals?
There are no signs the coronavirus pandemic is slowing down in the U.S., with more than 1,100 Americans dying every day from COVID-19 in recent days. Beyond the staggering fatalities, one estimate by the Australian National University puts the virus' potential global economic damage at over $21 trillion. The need for a coronavirus vaccine has thus become paramount to saving lives and mitigating economic catastrophes.
